Specific Consent Restrictions
Consent restricts use of biospecimens to research related to predictors of coronary heart disease progression.

Objectives

To conduct a trial to test the hypothesis that patients with stable coronary artery disease and normal or slightly reduced left ventricular function derive therapeutic benefit from the addition of ACE inhibitors to modern conventional therapy.

Background

Angiotensin-converting-enzyme (ACE) inhibitors are effective in reducing the risk of heart failure, myocardial infarction, and death from cardiovascular causes in patients with left ventricular systolic dysfunction or heart failure. ACE inhibitors have also been shown to reduce atherosclerotic complications in patients who have vascular disease without heart failure.

Subjects

The trial was a double-blind, placebo-controlled study in which 8290 patients were randomly assigned to receive either trandolapril at a target dose of 4 mg per day (4158 patients) or matching placebo (4132 patients).

Conclusions

In patients with stable coronary heart disease and preserved left ventricular function who are receiving "current standard" therapy and in whom the rate of cardiovascular events is lower than in previous trials of ACE inhibitors in patients with vascular disease, there is no evidence that the addition of an ACE inhibitor provides further benefit in terms of death from cardiovascular causes, myocardial infarction, or coronary revascularization. (NEJM 2004;351:2058-2068)

Please note that biospecimen availability is subject to review by the NHLBI, BioLINCC, and the NHLBI Biorepository. Certain biospecimens may not be made available for your request. Section 3 of the
BioLINCC handbook
describes the components of the review process

Visits (Vials):

03/04/2019

Serum

Plasma

Urine

Total

Baseline

7,354

21,255

6,712

35,321

Follow-up Visit 1

55

79

35

169

Follow-up Visit 2

1,244

1,561

724

3,529

Follow-up Visit 3

701

889

388

1,978

Follow-up Visit 4

1,823

2,312

1,002

5,137

Follow-up Visit 5

1,017

1,276

545

2,838

Follow-up Visit 6

2,820

3,517

1,546

7,883

Follow-up Visit 7

1,274

1,644

675

3,593

Follow-up Visit 8

2,220

2,783

1,232

6,235

Follow-up Visit 9

427

561

230

1,218

Follow-up Visit 10

423

585

238

1,246

Follow-up Visit 11

110

154

57

321

Follow-up Visit 12

29

38

18

85

Unknown

1,511

2,097

736

4,344

Visits (Subjects):

03/04/2019

Serum

Total number of subjects

Average volume (ml) per subject

Baseline

3,701

0.99

Follow-up Visit 1

13

2.12

Follow-up Visit 2

251

2.48

Follow-up Visit 3

141

2.49

Follow-up Visit 4

369

2.49

Follow-up Visit 5

207

2.49

Follow-up Visit 6

571

2.47

Follow-up Visit 7

258

2.49

Follow-up Visit 8

450

2.48

Follow-up Visit 9

86

2.67

Follow-up Visit 10

86

2.63

Follow-up Visit 11

22

2.50

Follow-up Visit 12

6

2.42

Unknown

306

2.48

Plasma

Total number of subjects

Average volume (ml) per subject

Baseline

3,770

1.94

Follow-up Visit 1

13

2.98

Follow-up Visit 2

251

3.17

Follow-up Visit 3

140

3.25

Follow-up Visit 4

368

3.13

Follow-up Visit 5

208

3.03

Follow-up Visit 6

573

3.12

Follow-up Visit 7

260

3.24

Follow-up Visit 8

450

3.23

Follow-up Visit 9

87

3.58

Follow-up Visit 10

86

3.50

Follow-up Visit 11

22

3.76

Follow-up Visit 12

6

2.83

Unknown

306

3.48

Urine

Total number of subjects

Average volume (ml) per subject

Baseline

3,367

11.32

Follow-up Visit 1

12

14.58

Follow-up Visit 2

242

14.96

Follow-up Visit 3

130

14.92

Follow-up Visit 4

335

14.96

Follow-up Visit 5

184

14.81

Follow-up Visit 6

516

14.98

Follow-up Visit 7

225

15.00

Follow-up Visit 8

413

14.92

Follow-up Visit 9

77

14.94

Follow-up Visit 10

80

14.88

Follow-up Visit 11

19

15.00

Follow-up Visit 12

6

15.00

Unknown

244

15.30

Requests for Open BioLINCC Studies are submitted through this website. Click the Request button to begin.

Persons using assistive technology may not be able to fully access information in the study documents. For assistance,
Contact BioLINCC and include the web address and/or publication title in your message. If you need help accessing information
in different file formats such as PDF, XLS, DOC, see Instructions for Downloading Viewers and Players.